Diagnosis

Released 10 February 2026     Expires: 10 February 2028      Programme: Cardiac amyloidosis 1 CPD/CME credit

Sponsorship Statement: Pfizer Ltd has provided OmniaMed Communications Ltd with a sponsorship for the creation of this British Journal of Cardiology e-learning programme in cardiac amyloidosis. Pfizer Ltd has had input into the content and author selection.
PP-VYN-GBR-2999 │ February 2026

Designed to provide healthcare professionals with a clear foundation of knowledge on cardiac amyloidosis. This module introduces the clinical presentation and pathophysiology of amyloidosis, highlights “red flag” features, and outlines contemporary non-invasive diagnostic approaches, emphasising the importance of early and accurate diagnosis.

Learning objectives

After completing this module, participants should be better able to understand:

  • Clinical phenotypes and “red flag” features of cardiac amyloidosis
  • The full spectrum of cardiac manifestations in amyloidosis and their clinical implications
  • How to apply a structured, non-invasive approach to diagnosing cardiac amyloidosis

Faculty

Dr Rob Cooper, Consultant Cardiologist, Liverpool Heart and Chest Hospital, NHS Foundation Trust

Accreditation

1 CPD/CME credit, 1 hours
BJC Learning has assigned one hour of CPD/CME credit to this module

You need to login to take this module

You need to be a registered member to view this page. It's quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.

THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT

All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.